May 28, 2026 11:00AM
May 28, 2026 11:00AM
May 27, 2026 08:01AM
May 27, 2026 08:00AM
May 19, 2026 06:48AM
May 13, 2026 08:30AM
May 13, 2026 07:30AM Altimmune Announces First Quarter 2026 Financial Results and Business Update
May 13, 2026 07:15AM
Mar 27, 2026 10:53AM
Mar 17, 2026 06:46AM
Mar 5, 2026 11:31AM
Mar 5, 2026 07:00AM
Jan 29, 2026 05:54PM
Jan 29, 2026 05:54PM Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Jan 27, 2026 09:25PM
Jan 27, 2026 09:25PM
Jan 27, 2026 06:32AM
Jan 5, 2026 07:31AM
Jan 5, 2026 07:30AM
Dec 19, 2025 06:30AM
Dec 19, 2025 06:30AM Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM
Nov 12, 2025 04:47AM
Nov 11, 2025 08:52AM
Nov 11, 2025 08:51AM
Nov 7, 2025 08:06AM
Nov 7, 2025 08:05AM Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
Nov 6, 2025 07:00AM
Nov 3, 2025 07:30AM
Nov 3, 2025 07:30AM
Oct 20, 2025 07:30AM
Sep 29, 2025 07:30AM
Sep 29, 2025 07:30AM
Aug 19, 2025 07:30AM Altimmune receives FDA fast track designation for pemvidutide in AUD
Aug 19, 2025 07:30AM
Aug 12, 2025 07:00AM
Aug 11, 2025 07:30AM
Aug 11, 2025 07:30AM
Jul 9, 2025 07:30AM
Jul 9, 2025 07:30AM
Jun 26, 2025 07:02AM Altimmune (ALT) Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide
Jun 26, 2025 07:00AM
Jun 25, 2025 07:12PM
Jun 13, 2025 07:30AM
May 19, 2025 07:31AM
May 19, 2025 07:30AM
May 13, 2025 07:00AM
May 8, 2025 07:30AM Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
May 1, 2025 07:30AM

322,963 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All